Progressive muscle relaxation plus walking to reduce fatigue in adults on dialysis
Official title: Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
Run by University of Illinois Chicago · NCT07014111 · Data updated 2026-11-12
This program will try progressive muscle relaxation combined with regular walking to see if it reduces fatigue for adults receiving in-center hemodialysis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Illinois Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | September 2, 2025 |
| Main results expected | February 2027 |
| Study ends | June 2027 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT07014111 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with end-stage kidney disease on in-center hemodialysis for ≥3 months who report fatigue (VAS ≥4), can stand and walk one block, read English, and have a cell phone that receives texts.
✕Probably not a fit
Patients with unstable angina or pulmonary disease, major lower-extremity amputation without a prosthetic, significant cognitive impairment, inability to walk, or whose nephrologist disallows participation are unlikely to benefit or to be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial enrolls adults with end-stage kidney disease receiving in-center hemodialysis who report clinically meaningful fatigue. Participants are randomized to a combined progressive muscle relaxation and walking program or an attention-control condition, with support delivered in part by text messages. The team will track feasibility measures (adherence, retention) and acceptability (participant feedback) while measuring changes in fatigue and functional ability. Eligible patients must be English-speaking, able to stand and walk one block, have a cell phone for texts, and have been on hemodialysis for at least three months.
Why it matters
Potential benefit: If successful, this low-risk program could reduce fatigue and improve daily functioning and quality of life for adults on hemodialysis.
How similar studies have gone: Prior trials of exercise and relaxation techniques have shown benefits for fatigue in dialysis populations, but combining progressive muscle relaxation with a walking program is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months * Can read and speak English * Fatigue measured via visual analogue scale, score ≥4 over the last week * Able to stand and walk one block * Has a cell phone that can receive text messages Exclusion Criteria: * Patient's nephrologist refuses for them to participate * Unstable angina * Unstable pulmonary disease or pulmonary symptoms that preclude participation * Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles- * Cognitive impairment that, in the judgement of the research team, precludes trial participation * Participation in the formative phase of the development of Fight Fatigue
Where it's running
-
UI Health/University of Illinois Chicago
Chicago, Illinois, United States Recruiting
Study contacts
- Study coordinator: Mary Hannan, PhD
- Email: mhanna22@uic.edu
- Phone: 3123554838
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How the body handles fosmanogepix in adults on dialysis
This study tests how fosmanogepix behaves in the body and its safety in adults with end-stage kidney disease on dialysis, compared to people with normal kidney function.
-
Coated Aldehyde Oxystarch to lower PBUTs in adults on dialysis
This study tests whether a coated oral adsorbent called Coated Aldehyde Oxystarch (Xiqing) can lower protein-bound uremic toxins in adults on maintenance dialysis and checks its safety.
-
Changes in regional ventilation-perfusion after artery graft ballooning in dialysis patients
This study tests how the lungs' ventilation and blood flow respond right before, during, and after repairing an arteriovenous graft with balloon angioplasty in adults on dialysis.
-
Four-hour pHA130 hemoadsorption with hemodialysis
We will test whether using pHA130 hemoadsorption for 4 hours instead of 2 during regular dialysis removes more protein-bound toxins like indoxyl sulfate in people on maintenance hemodialysis.
-
CRISPR-edited donor kidney transplant to reduce rejection risk
This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.
-
AP306 at fixed doses in adults on dialysis with high phosphate
This trial tests if AP306, taken daily at different doses, can safely lower phosphate levels in adults on maintenance dialysis with hyperphosphatemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.